<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398554</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000514344</org_study_id>
    <secondary_id>GPOH-HD-2002-PILOT-VECOPA</secondary_id>
    <secondary_id>EU-20652</secondary_id>
    <secondary_id>EUDRACT-2004-005244-28</secondary_id>
    <nct_id>NCT00398554</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma</brief_title>
  <official_title>Pilot Study for Therapy Optimising for Hodgkin's Lymphoma in Childhood and Adolescence; Optimising Therapy for Boys With Hodgkin's Lymphoma in Intermediate and Advanced Stages. Safety and Efficacy Study for Drug Combination VECOPA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christine Mauz-Körholz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
      cells, either by killing the cells or by stopping them from dividing. Giving combination
      chemotherapy may kill more cancer cells.

      PURPOSE: This phase II trial is studying the side effects and how well combination
      chemotherapy works in treating young male patients with Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the safety and efficacy of combination chemotherapy comprising vincristine,
           etoposide, cyclophosphamide, vinblastine, prednisone, and doxorubicin hydrochloride
           (VECOPA) in pediatric male patients with previously untreated stage II-IV classic
           Hodgkin's lymphoma.

        -  Compare the effects of VECOPA vs cyclophosphamide, vincristine, procarbazine
           hydrochloride, and prednisone (COPP) in these patients.

      OUTLINE: This is a pilot, multicenter study. Patients are stratified according to disease
      stage (IA/B[E], IIA[E], IIB, or IIIA vs IIB[E], IIIA/B[E], IIIB, or IVA/B).

        -  Stratum 1 (stages IA/B[E], IIA[E], IIB, or IIIA): Patients receive oral prednisone on
           days 1-15, vincristine IV on days 1, 8, and 15, doxorubicin hydrochloride IV over 4
           hours on days 1 and 15, and etoposide IV over 2 hours on days 2-6 (OEPA). Treatment
           repeats every 4 weeks for 2 courses. Beginning at week 9, patients receive VECOPA
           chemotherapy comprising oral prednisone on days 1-14 and 21-34, etoposide IV over 2
           hours on days 1-3, doxorubicin hydrochloride IV over 2 hours on day 21, vinblastine IV
           and cyclophosphamide IV over 1 hour on days 1 and 21, and vincristine IV on days 8 and
           29. Patients then undergo radiotherapy.

        -  Stratum 2 (stages IIB[E], IIIA/B[E], IIIB, or IVA/B): Patients receive 2 courses of OEPA
           as in stratum 1 followed by 2 courses of VECOPA (6-week courses). Patients then undergo
           radiotherapy.

      After completion of study treatment, patients are followed periodically for at least 6 years.

      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity at days 21 and 42 (+/- 2 days) of treatment</measure>
    <time_frame>days 21 and 42 (+/- 2 days) of treatment after start of VECOPA cycle</time_frame>
    <description>number of VECOPA cycles that allow continuation of chemotherapy on a sufficient hematopoietic recovery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>event-free survival at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>overall survival at 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>VECOPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose and time intensified consoloditation chemotherapy cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21</description>
    <arm_group_label>VECOPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>25mg/m²/day, 2 hours i.v.infusion on day 21</description>
    <arm_group_label>VECOPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>150 mg/m²/day, 2 hours i.v.infusion (intravenous drip) on days 1 - 3</description>
    <arm_group_label>VECOPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>40 mg/m2/day p.o. (intake by mouth)divided in 3 single doses daily from day 1 - 14 and day 21 - 34</description>
    <arm_group_label>VECOPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine sulfate</intervention_name>
    <description>6 mg/m² i.v. bolus on day 1 and day 21</description>
    <arm_group_label>VECOPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>1,5 mg/m2 i.v. bolus max. single dose 2 mg (cap dose at 2 mg) on day 8 and day 29</description>
    <arm_group_label>VECOPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>involved field irradiation, single daily fractions 1,5 Gy to max. 1,8 Gy standard dose 20 Gy, max dose 30 Gy (boost irradiation if required)</description>
    <arm_group_label>VECOPA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of classic Hodgkin's lymphoma (HL)

               -  Intermediate or advanced disease (stage I[E]-IV)

          -  No lymphocyte-predominant HL

          -  Previously untreated disease

        PATIENT CHARACTERISTICS:

          -  Male

          -  No known hypersensitivity or contraindication to study drugs

          -  No other concurrent malignancies

          -  No severe concurrent diseases (e.g., immune deficiency syndrome)

          -  No known HIV positivity

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior chemotherapy or radiotherapy

          -  More than 30 days since prior and no other concurrent investigational drugs

          -  More than 30 days since prior and no concurrent participation in another clinical
             trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Koerholz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Martin-Luther-Universität Halle-Wittenberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>D-86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite University Medical Center of Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>D-13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaetsklinik I at the University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>D-50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsfrauenklinik Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>D-06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik A - Universitaetsklinikum Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderklinik d. TU / Schwabing</name>
      <address>
        <city>Munich</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>D-26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2006</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Christine Mauz-Körholz</investigator_full_name>
    <investigator_title>Study Secretary of the EuroNet-PHL group</investigator_title>
  </responsible_party>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>childhood lymphocyte depletion Hodgkin lymphoma</keyword>
  <keyword>childhood mixed cellularity Hodgkin lymphoma</keyword>
  <keyword>childhood nodular sclerosis Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

